Becker Muscular Dystrophy Pipeline 2026: Therapeutic Candidates, Clinical Trial Insights, and Companies Leading Drug Development | Epirium Bio, Immuno Forge, Italfarmaco, Santhera Pharma, Edgewise

“Becker Muscular Dystrophy Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Becker Muscular DystrophyPipeline Landscape.

The Becker Muscular Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Becker Muscular Dystrophy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Becker Muscular Dystrophy treatment therapies with a considerable amount of success over the years. Becker Muscular Dystrophy Key players such as – Epirium Bio, Immuno Forge, Italfarmaco, Santhera Pharmaceuticals, Edgewise Therapeutics, and others, are developing therapies for the Becker Muscular Dystrophy treatment

• Becker Muscular Dystrophy Emerging therapies such as – EPM-01, PF1801, Givinostat, Vamorolone, EDG 5506, and others are expected to have a significant impact on the Becker Muscular Dystrophy market in the coming years.

• In October 2026, Edgewise Therapeutics is developing sevasemten (EDG-5506), an investigational oral small-molecule therapy intended to minimize muscle damage caused by muscle contractions. The Phase III-enabling GRAND CANYON study enrolled 175 adults with Becker muscular dystrophy (BMD), with results anticipated in the fourth quarter of 2026 based on the company’s previously announced timeline. This study represents a significant milestone in evaluating sevasemten’s potential to slow functional deterioration in patients with BMD.

• In September 2026, clinical trial update listed ReveraGen BioPharma’s Phase II pilot study of vamorolone (NCT05166109) as completed. The randomized, double-blind, placebo-controlled trial assessed the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of oral vamorolone in males with Becker muscular dystrophy (BMD) over a 24-week period. However, completion of the study alone does not confirm the treatment’s efficacy or imply regulatory approval.

• In July 2026, A July 2026 study published in eBioMedicine presented findings from a completed Phase Ib, open-label trial evaluating sevasemten in 12 adults with Becker muscular dystrophy (BMD). The treatment was generally well tolerated, with no serious adverse events or treatment discontinuations due to adverse events reported. Muscle-injury biomarkers decreased and remained lower during follow-up of up to 24 months, while North Star Ambulatory Assessment scores remained stable. Although these results are promising, the small study population limits the conclusions, and efficacy has not yet been established in a pivotal clinical trial.

• In June 2025, Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a prominent biopharmaceutical company focused on muscle diseases, has announced encouraging results from its sevasemten program targeting Becker and Duchenne muscular dystrophies. The company shared positive findings from the MESA open-label extension trial, which offers continued access to sevasemten for Becker patients previously involved in the ARCH study or who completed the CANYON, GRAND CANYON, or DUNE trials. As of the March 2025 data cutoff, 99% of eligible participants (n=85) had enrolled in the MESA study.

• In January 2025, The US FDA has granted orphan drug designation to IPS Heart’s GIVI-MPC, an investigational stem cell therapy designed to stimulate muscle tissue regeneration in patients with muscular dystrophy, particularly Becker muscular dystrophy (BMD). This designation applies to therapies targeting rare diseases affecting fewer than 200,000 people in the United States and provides development incentives, including potential tax benefits and seven years of market exclusivity if the treatment receives FDA approval.

Becker Muscular Dystrophy Overview

Becker Muscular Dystrophy (BMD) is a genetic disorder characterized by progressive muscle weakness and wasting. It primarily affects boys and men, typically manifesting in adolescence or early adulthood. BMD is caused by mutations in the gene that encodes dystrophin, a protein essential for maintaining muscle structure and function.

Get a Free Sample PDF Report to know more about Becker Muscular Dystrophy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/becker-muscular-dystrophy-pipeline-insight

Emerging Becker Muscular Dystrophy Drugs Under Different Phases of Clinical Development Include:

• EPM-01: Epirium Bio

• PF1801: ImmunoForge

• Givinostat: Italfarmaco

• Vamorolone: Santhera Pharmaceuticals

• EDG 5506 : Edgewise Therapeutics

Becker Muscular Dystrophy Pipeline Therapeutics Assessment

• Becker Muscular Dystrophy Assessment by Product Type

• Becker Muscular Dystrophy By Stage and Product Type

• Becker Muscular Dystrophy Assessment by Route of Administration

• Becker Muscular Dystrophy By Stage and Route of Administration

• Becker Muscular Dystrophy Assessment by Molecule Type

• Becker Muscular Dystrophy by Stage and Molecule Type

DelveInsight’s Becker Muscular Dystrophy Report covers around 8+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Becker Muscular Dystrophy product details are provided in the report. Download the Becker Muscular Dystrophy pipeline report to learn more about the emerging Becker Muscular Dystrophy therapies

Becker Muscular Dystrophy Pipeline Analysis:

The Becker Muscular Dystrophy pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the Becker Muscular Dystrophy treatment with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Becker Muscular Dystrophy Treatment.

• Becker Muscular Dystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Becker Muscular Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Becker Muscular Dystrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Becker Muscular Dystrophy drugs and therapies

Becker Muscular Dystrophy Pipeline Market Drivers

• Rising incidence of Becker Muscular Dystrophy

• Improving Healthcare Infrastructure

• Demand for New and Effective Drugs

Becker Muscular Dystrophy Pipeline Market Barriers

• Currently no approved drugs for Becker Muscular Dystrophy in any country

• Very few clinical investigational efforts underway for Becker Muscular Dystrophy

Scope of Becker Muscular Dystrophy Pipeline Drug Insight

• Coverage: Global

• Key Becker Muscular Dystrophy Companies: Epirium Bio, Immuno Forge, Italfarmaco, Santhera Pharmaceuticals, Edgewise Therapeutics, and others

• Key Becker Muscular Dystrophy Therapies: EPM-01, PF1801, Givinostat, Vamorolone, EDG 5506, and others

• Becker Muscular Dystrophy Therapeutic Assessment: Becker Muscular Dystrophy current marketed and Becker Muscular Dystrophy emerging therapies

• Becker Muscular Dystrophy Market Dynamics: Becker Muscular Dystrophy market drivers and Becker Muscular Dystrophy market barriers

Request for Sample PDF Report for Becker Muscular Dystrophy Pipeline Assessment and clinical trials

Table of Contents

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services